Ligand Pharmaceuticals Incorporated (LGND)

From In-House Drug Developer to Biopharma Royalty Aggregator

If you remember Ligand Pharmaceuticals (LGND) as a biotech that developed its own drugs, that story ended a while ago. Since 2023, Ligand has fully transformed into a pure-play biopharma royalty aggregator — a company that buys or licenses royalty streams on drugs developed by other companies, then collects a royalty check every time those drugs sell. No in-house commercialization risk, no large sales force, no full R&D cost burden of a typical drug developer. This is a capital-light model: high margins, low commercial risk, but fully dependent on partners' sales success.

Three Key Transformation Steps

Year	Event	Impact
2023	OmniAb spin-off (antibody-discovery platform)	Divested the R&D-heavy segment to focus 100% on royalties
July 2025	Pelthos/Channel Therapeutics merger	ZELSUVMI (molluscum gel) spun into a new entity (NYSE American: PTHS); Ligand invested USD18M but retained a 13% worldwide royalty
July 2026	XOMA Royalty acquisition (USD739M, all-cash)	Royalty portfolio expanded from ~80-90 assets to 200+ royalty assets, including 7 new commercial-stage products

What Drives Revenue Today

Two royalty assets currently drive the bulk of Ligand's growth:

• Filspari (Travere Therapeutics — FSGS kidney disease drug): partner net sales USD141M in Q2 2026, up 96% YoY, riding FDA full-approval momentum
• Ohtuvayre (Merck, via its acquisition of Verona Pharma — COPD drug): partner net sales USD204M in Q2 2026, up 98% YoY, now backed by Merck's larger commercial muscle
• Zelsuvmi (Pelthos) — a smaller but consistent royalty contributor

Following the XOMA acquisition (closed July 14, 2026), Ligand's portfolio now spans more than 200 royalty assets — 7 of which are new commercial products that add diversification beyond Filspari and Ohtuvayre alone.

Management

CEO Todd Davis has openly led this transformation strategy, consistently framing each step (OmniAb, Pelthos, XOMA) as part of one coherent goal: becoming a smaller, faster-growing challenger to the dominant player in the space, Royalty Pharma (RPRX).

Shariah Compliance Status

✅ SHARIAH COMPLIANT (per Zoya reference). The pharmaceutical royalty business model (no riba, no prohibited products) qualifies LGND as Shariah-compliant for Malaysian investors following this screening standard.

Revenue Trend — Growth Accelerated by Royalties

Ligand's revenue has grown sharply over the past two years, driven almost entirely by Filspari and Ohtuvayre royalty momentum:

Period	Total Revenue	YoY Growth
FY2024 (full year)	USD167.1M	—
Q1 2025	USD45.3M	—
Q2 2025	USD47.6M	—
FY2025 (full year)	USD268.1M	+60%
Q1 2026	USD51.7M	+14% vs Q1 2025
Q2 2026	USD63.7M	+34% vs Q2 2025
FY2026 (guidance)	USD270-310M	Roughly +1% to +16% (estimated)

Q2 2026 Detail (quarter ended June 30, 2026)

• Total revenue: USD63.7M (+34% YoY)
• Royalty revenue: USD48.0M (+32% YoY) — driven by Filspari (+96% partner sales) and Ohtuvayre (+98% partner sales)
• GAAP EPS: USD2.22 | Adjusted EPS: USD2.37 (beat consensus of USD1.95)

FY2026 Guidance

Management raised guidance twice through 2026: revenue now expected at USD270-310M (royalty revenue USD225-250M), adjusted EPS USD9.00-9.50 — up from an initial USD8.50-9.50 estimate. This reflects management confidence in continued Filspari/Ohtuvayre momentum plus incremental contribution from the newly-integrated XOMA portfolio.

Deeper analysis on earnings quality (including a historical one-off gain), full capital structure detail, and sensitivity to royalty deceleration is available to Gold Members.

No Dividend — And Here's Why

Ligand Pharmaceuticals does not pay a dividend — it never has in the company's history. TTM (trailing twelve months) yield is 0.00%.

This isn't a weakness — it's a strategic decision consistent with the company's current growth phase. As a royalty aggregator still in an active expansion phase (having just completed a USD739M XOMA acquisition in July 2026), every dollar of cash generated from existing royalties (Filspari, Ohtuvayre, Zelsuvmi) is being redeployed into buying new royalty assets — not distributed to shareholders.

The logic is simple: as long as management believes it can generate a higher return than its cost of capital by buying more royalty streams (versus paying a dividend), this capital redeployment is a more valuable use of cash for long-term shareholders — even though it means no dividend income in the near term.

This is a common pattern for growth-stage royalty aggregators — full focus on portfolio growth, not cash distribution.